As a clinically heterogeneous subtype of breast cancer, triple-negative breast cancer (TNBC) is associated with a poor clinical outcome and a high relapse rate. Conventional chemotherapy and radiotherapy are effective treatments for patients with TNBC. However, the prognosis of TNBC remains unsatisfactory. Therefore, a large volume of research has explored the molecular markers and oncogenic signaling pathways associated with TNBC, including the cell cycle, DNA damage response and androgen receptor (AR) signaling pathways, to identify more efficient targeted therapies. However, whether these predicted pathways are effective targets has yet to be confirmed. In the present review, potentially carcinogenic signaling pathways in TNBCs from previous reports were considered, and ultimately five tumorigenic signaling pathways were selected, specifically receptor tyrosine kinases and downstream signaling pathways, the epithelial-to-mesenchymal transition and associated pathways, the immunoregulatory tumor microenvironment, DNA damage repair pathways, and AR and coordinating pathways. The conclusions of the preclinical and clinical trials of each pathway were then consolidated. Although a number of signaling pathways in TNBC have been considered in preclinical and clinical trials, the aforementioned pathways account for the majority of the malignant behaviors of TNBC. Identifying the alterations to different carcinogenic signaling pathways and their association with the heterogeneity of TNBC may facilitate the development of optimal precision medical approaches for patients with TNBC, potentially improving the efficiency of anticancer therapy.
triple-negative breast cancerprecision medicinecarcinogenic pathwaytargeted therapyclinical treatmentIntroduction
Breast cancer is the leading cause of cancer-associated mortality for women. In 2012, 1.7 million people were diagnosed with breast cancer worldwide, and 521,900 succumbed to the complications (1). Given the varied prognosis and response to treatment of patients with breast cancer, the molecular classification of breast cancer has been examined to improve the understanding of this disease. Triple-negative breast cancer (TNBC), which was first reported in the literature in 2005, is a molecular subset of breast cancer. TNBC is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression (2), and accounts for 16% of all breast cancer cases (3). Although TNBC tumors display relatively simple molecular phenotypes, they are inherently heterogeneous. In particular, TNBCs exhibit varying morphology, gene expression and signaling pathway activity (4); thus, they have complicated clinicopathological features, to the detriment of the prognosis of patients with TNBC. TNBC was compared with other breast cancer subtypes in a retrospective analysis; increased risks of distant relapse [hazard ratio (HR), 2.6; P<0.0001] and mortality (HR, 3.2; P<0.001) in the first five years were identified (5). As established endocrine and targeted therapies are ineffective against TNBC, chemotherapy remains the primary regimen for TNBC treatment (6). TNBC is highly sensitive to cytotoxic chemotherapy (7), but this treatment is associated with relatively low rates of pathological response (8,9). Thus, developing a more effective therapeutic method for patients with TNBC is necessary.
With this objective, a number of studies have investigated the molecular classification of TNBC to determine optimal individualized therapy strategies for TNBC. Lehmann et al (4) indicated that TNBCs could be classified into the following subtypes according to gene expression profiles: Basal-like subtypes 1 and 2, immunomodulatory subtype, mesenchymal subtype, mesenchymal stem-like subtype, and luminal androgen receptor (AR) subtype. Alternatively, Burstein et al (10) reported that TNBCs could be divided into four subtypes: Basal-like/immune-suppressed subtype, basal-like/immune-activated subtype, mesenchymal subtype and luminal/AR subtype. Patients with specific tumor molecular abnormalities treated with molecularly matched targeted therapy respond better to therapy compared with those treated with non-matched targeted therapy (11). In the present review, the molecular markers and signaling pathways frequently dysregulated in TNBCs, and the targeted therapies in clinical trials and preclinical studies, will be summarized.
Receptor tyrosine kinases and downstream signaling pathways
RTKs are important components of signal transduction pathways in the regulation of proliferation, and are associated with two downstream signaling pathways in particular: The Ras/mitogen-activated protein kinase (MAPK) pathway, and the phosphoinositide 3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) pathway. The RTKs include epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR) 1–3, platelet-derived growth factor receptor (PDGFR) α/β, insulin-like growth factor receptor (IGFR), fibroblast growth factor receptor (FGFR), c-Met, and transforming growth factor receptor-β (TGFR-β), all of which are potential targets for TNBC therapy (4,12–16). EGFR dysregulation is the most commonly identified in TNBC tumors; 60–80% of TNBC tumors demonstrate EFGR overexpression (17,18). However, the applicability of anti-RTK drugs against TNBC are limited on account of biochemical multiplicity and toxicity (19). For example, lapatinib, a dual EGFR and HER2 TK inhibitor, is ineffective in patients with TNBC, although it is clinically effective against HER2-positive breast cancer. The mechanism of lapatinib resistance in TNBC may be associated with interleukin-6 expression (20). The inhibition of Src homology phosphotyrosyl phosphatase 2 (SHP2), an important molecule in EGFR/FGFR1/c-Met signaling (21), was reported to suppress TNBC tumorigenesis and metastasis in vitro (22), indicating the potential anti-tumor efficiency of RTK inhibitors in TNBC treatment. A number of RTK inhibitors have also exhibited promising anticancer therapeutic efficacy in a clinical setting. For example, bevacizumab is an anti-VEGF monoclonal antibody. In a single-arm and phase II multicenter study of bevacizumab, docetaxel, and carboplatin-based neoadjuvant treatment for patients with stage II/III TNBC, the results demonstrated a relatively high pathological complete response rate (42%) with a low risk of adverse events (23); additionally, adding bevacizumab to neoadjuvant chemotherapy regimens improved the pathological complete response rate among patients with TNBC (39.3 vs. 27.9%; P=0.003) (24).
Ras/MAPK pathway
The Ras/MAPK pathway promotes cell proliferation, cell differentiation and angiogenesis (25). Ras family members, including H-Ras, K-Ras and N-Ras, can be activated by RTKs to transmit growth signals from the cell membrane to the nucleus via a series of phosphorylated proteins, including Raf, MAPK kinase 1 (MEK) and extracellular signal-regulated kinases (ERK) 1/2 (26). Although the frequency of mutations in the Ras/MAPK signaling pathway is <2% in TNBC, copy number variations of certain genes from the Ras/MAPK pathway have been demonstrated to be associated with TNBC (26). For example, the overexpression of ERK is associated with a higher mortality rate in patients with TNBC (27). The MEK inhibitor selumetinib inhibited the motility and invasiveness of the MDA-MB-231 and SUM149 TNBC cell lines in vitro. In addition, selumetinib had a significant effect on the prevention of lung metastasis in a TNBC-bearing mouse xenograft model (25). These findings may provide evidence of the applicability of MEK inhibitors in TNBC treatment. However, certain genetic defects along the Ras/MAPK pathway, including the loss of negative regulators of MAPK signaling, such as phosphatase and tensin homolog (PTEN) and certain regulatory micro (mi)RNAs, such as the let-7 family, are also proposed to serve an important role in TNBC development (26). The Ras/MAPK pathway negatively regulates tumor immunogenicity by affecting the process of tumor antigen presentation in TNBC cells; compared with solo therapy, combining MEK inhibition and programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint inhibitors increased the therapeutic efficiency in a murine syngeneic TNBC model (28).
PI3K/AKT/mTOR pathway
PI3K family members are activated by RTKs. Activated PI3Ks phosphorylate phosphatidylinositol-4,5-diphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3), resulting in the downstream phosphorylation of AKT (29). Phosphorylated AKT then activates mTOR, a serine/threonine protein kinase, through the intermediary tuberous sclerosis complex 1/2 to promote protein synthesis and cell growth (30,31). PTEN serves an important tumor suppressor role in the process by inhibiting the dephosphorylation of PIP3 to PIP2 (32). The PI3K/AKT/mTOR pathway mediates a range of processes, including cell growth, survival and migration, and tumor formation and angiogenesis (33). The dysregulation of the PI3K/AKT/mTOR pathway occurs frequently in TNBC. PI3KCα-activating mutations are observed in 23.7% of TNBC patients (34), and PTEN loss mutations, including promoter silencing and functional suppression, are detected in 25–30% of TNBC cases (32,35,36). With regards to outcome, the hyperactivation of AKT and mTOR are associated with the poor prognosis of patients with TNBC, and based on success in preclinical experiments, dual inhibition of these molecules may represent a promising strategy for TNBC treatment (37–39).
The mTOR inhibitor everolimus has been approved by the US Food and Drug Administration (FDA), and can be combined with the aromatase inhibitor exemestane for patients with metastatic homologous recombination (HR)-positive breast cancer (40). The therapeutic effect of everolimus has been confirmed for patients with TNBC; mTOR activation may lead to platinum therapy resistance (41), and so everolimus combined with carboplatin has been proposed as an effective therapy for patients with metastatic TNBC (42). Phase I trials have also demonstrated that patients with metastatic TNBC who received a combination of chemotherapy and PI3K/AKT/mTOR inhibitor-based targeted therapy had a significantly prolonged median PFS time compared with patients who did not receive the targeted therapy (43). Another study reported that PI3K inhibition causes HR impairment and increased sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition in TNBC without breast cancer associated (BRCA) 1/2 mutations. Therefore, PI3K inhibition can improve the therapeutic efficiency of PARP inhibition in BRCA-wild type TNBC (44). Based on this observation, a clinical trial with BKM120 (buparlisib) and olaparib was initiated, as presented in Table I (45–67).
A high level of crosstalk between the Ras/MAPK and PI3K/AKT/mTOR pathways has been detected in basal-like breast cancer models (68), and an approach that inhibits both pathways may be feasible. However, the high toxicity levels of such an approach are concerning (69), so a greater understanding of the cross-talk mechanisms between pathways is required before effective targeted therapy of this type with improved tolerability can be developed.
Epithelial-to-mesenchymal transition and associated pathways
EMT is an essential biological process that also assists the migration and invasion of malignant tumor cells. Thus, elucidating the molecular mechanism of the EMT process and its association with the occurrence, development and metastasis of cancer is of great significance.
During EMT, epithelial cells lose the expression of E-cadherin and acquire mesenchymal markers, including vimentin (70). There is evidence to indicate that a number of RTKs, including EGFR, IGF1R, hepatocyte growth factor receptor and c-Met, non-RTKs, including Src, and embryonic transcription factors, including Twist and Slug (71–77), can induce EMT. Diverse signaling pathways, including MAPKs, PI3K and nuclear factor-κB, also promote EMT (76,78). Other pathways, including Notch and Wnt/β-catenin signaling pathways, are also associated with EMT (79). Tumor cells undergoing EMT may acquire stem cell-like phenotypes and migratory abilities (80). Previous studies have indicated that the genes involved in EMT and conversion to the cancer stem cell phenotype are activated in TNBC (4,81). Additional studies have demonstrated that EMT may induce the resistance to chemotherapy and radiotherapy (82), and may thus have potential as a therapeutic target in TNBC.
In preclinical trials, miRNAs have been demonstrated to regulate tumor EMT and metastasis by inhibiting the expression of certain genes (83). For example, a previous study indicated that miR-200b-3p and miR-200b-5p synergize to suppress TNBC cell migration by inhibiting EMT (84). This finding may provide a novel strategy for clinical treatment. Furthermore, protein tyrosine kinase 6 (PTK6) is an intracellular non-receptor kinase that can promote EMT and regulate the metastasis of TNBC cells by modulating E-cadherin expression. PTK6 inhibition may prevent the metastasis of TNBC cells, and thus exhibits clinical potential for improving the treatment strategies for patients with mesenchymal TNBC (85). Considering the association of EMT with breast cancer stem cells (80), aldehyde dehydrogenase 1 (ALDH1) inhibitors were proposed as a therapeutic alternative in TNBC therapy, targeting the characteristic ALDH1 phenotypic marker of breast cancer stem cells (86,87). A preclinical study confirmed that LBH589, a histone deacetylase inhibitor, could inhibit the metastasis of TNBC cells by partially reversing EMT (88).
Wnt/β-catenin pathway
Aberrant regulation of the Wnt signaling pathway serves an important role in tumorigenesis (89). This regulation is associated with EMT and self-renewal in breast cancer, as it regulates the transcription factors Twist and Slug (90,91).
During tumorigenesis, the Wnt ligand binds to Frizzled (Fz), a seven-pass transmembrane surface receptor, and its co-receptor, low-density lipoprotein receptor-related 5/6 (LRP5/6), to form a Wnt-Fz-LRP6 complex. The combination of this complex with the protein Dishevelled can elicit the phosphorylation of LRP6 and the recruitment of the axin complex, which is composed of axin, anaphase-promoting complex, casein kinase 1 and glycogen synthase kinase 3. These events ultimately stabilize β-catenin, which is degraded by the axin complex without Wnt. The β-catenin protein is transferred to the nucleus where it activates the transcription of Wnt target genes (92).
Lehmann et al (4) demonstrated that TNBC has a unique Wnt/β-catenin pathway gene expression. Other studies have indicated that the activation of the Wnt pathway is associated with poor prognosis and metastasis in patients with TNBC (93). Thus, the Wnt/β-catenin pathway could be utilized as a target for TNBC therapy. Substantial efforts targeting the Wnt pathway have been made, but few have reached the clinical trial stage thus far. LGK974, a molecular inhibitor of Wnt secretion, has been evaluated in stage I trials in several types of cancer, including TNBC (http://www.clinicaltrials.gov). In preclinical trials, a previously FDA-approved anti-helminthic drug niclosamide, which can reduce LRP6 and β-catenin levels in vitro, was reported to suppress the growth of basal breast cancer xenografts in vivo (94,95). Thus, niclosamide may be a promising drug for clinical trials. Another FDA-approved, anti-leprosy drug, clofazimine, was observed to suppress the growth of TNBC cells through the inhibition of the Wnt/β-catenin pathway (94). Notably, the multipurpose drug suramin can inhibit the Wnt signaling pathway and the proliferation of TNBC cells in vitro and in vivo. Such findings may pave the way for the discovery of novel targeted therapies against Wnt-dependent TNBC tumors (96).
TGF-β/Smad pathway
In addition to the Wnt pathway, the TGF-β/Smad pathway can also regulate cell proliferation, invasion, apoptosis and metastasis, and induce EMT, and thus has potential in targeted strategies against TNBC (97). When secreted from cells, TGF-β remains as an inactive, latent homodimeric polypeptide (98). TGF-β can be activated by hydrolyzing the latent complex. The TGF-β then binds to and activates its receptors, TGF-β receptor type II (TβRII) and I (TβRI), which are transmembrane serine/threonine kinases. This induces two TβRI and two TβRII molecules to form a heterotetramer, and TβRII triggers the cross-phosphorylation of TβRI, allowing the activation of substrate Smad proteins (99). Smads include receptor-regulated Smads (R-Smads), common mediator Smads (Co-Smads) and inhibitory Smads (I-Smads). Among the Smad types, Smad-2 and Smad-3, as R-Smads, are the direct substrates of TβRI. The activated R-Smads combine with Smad-4, a Co-Smad, where they induce the activation of specific genes. Inversely, Smad-7, as an I-Smad, can inactivate the TGF-β/Smad pathway by disrupting the combination of R-Smad with TβRI (100).
Smad-2 or Smad-3 overexpression, when combined with Smad-4, can induce EMT. Inversely, the reduced expression of Smad-2, Smad-3 and Smad-4, or the overexpression of Smad-7, can constrain EMT (101). Clinical evidence suggests that ~40% of human breast cancer tumors have high TGFβ1, TGFβ2, Smad-3 and Smad-4 expression levels, although the positive TGFβ gene signature occurs primarily in ER-positive breast tumors and lung metastases (102). In addition, a high TGF-β1 expression level was detected in TNBC cells (MDA231, Hs578T, HCC1806) compared with non-TNBC (BT474, ZR75-1, SKBR3) (103). Treatment with zerumbone may inhibit the tumorigenicity of TNBC cells by suppressing the TGFβ/Smad pathway, and thus has a potential as a targeted drug for TNBC. LY2109761, another selective TβRI/II dual inhibitor, can also suppress the invasion and motility of TNBC cells (103). The antidiabetic agent metformin can hinder the TGF-β/Smad pathway by disrupting the activation of Smad-2 and Smad-3 in TNBC (104). This finding may offer a novel perspective for the clinical treatment of TNBC patients.
Although chemotherapy is the central treatment methodology against TNBC, patients with TNBC are likely to eventually develop drug resistance and disease recurrence, which is contributed to by cancer stem-like cells. The TβRI inhibitor LY2157299 can constrain the development of stem-like cells, indicating the potential combination of chemotherapy and TGF-β targeted drugs in clinical trials (105).
Androgen receptor and coordinating pathways
ER and PR are widely accepted molecular markers in the occurrence, development and prognosis of breast cancer. TNBC tumors lack ER and PR expression. An association between TNBC and AR, another hormone receptor, has been observed (4). Lehmann et al (4) classified cases of TNBC according to gene expression profiling, in which a luminal AR subtype, featuring increased gene expression in the AR signaling pathway, was identified. In another study of 593 TNBC cases, a luminal AR subtype was also identified based on the expression profiles and histopathological features of primary TNBC tumors (106).
As a member of the steroid hormone receptor family, AR is expressed in ~77% of breast cancer tumors (107), and serves an important role in regulating cell proliferation (108). Testosterone, particularly dihydrotestosterone, is the main activator of AR (109). Subsequent to ligand binding, AR is usually bound to chaperone proteins, including heat shock proteins, before forming a homodimer. The homodimer translocates to the nucleus and promotes the transcription of target genes (110).
Anti-androgens are the most common drugs for treating AR-positive cancer, including AR-positive TNBC. In recent research, bicalutamide (150 mg daily) was prescribed to 424 patients with AR-positive, ER and PR-negative metastatic breast cancer. The six-month clinical beneficial rate was 19% [95% confidence interval (CI), 7–39%], and the median progression-free survival time was 12 weeks (95% CI, 11–22 weeks). These findings provided evidence in favor of the application of anti-androgen therapy in ER/PR-negative and AR-positive breast cancer (111). In a phase II clinical trial of enzalutamide, another AR antagonist, considerable beneficial therapeutic efficiency was demonstrated in AR-positive TNBC patients, indicating the potential efficacy of anti-AR therapy in clinical settings (clinicaltrials.gov: NCT01889238).
A previous study indicated that the concomitant administration of the anti-androgen bicalutamide with a EGFR, PDGFRβ or Erk1/2 inhibitor significantly decreased the AR expression level when compared with the single administration of the inhibitors (112). Another study reported that activating PIK3CA mutations are enriched in AR-positive TNBCs, potentially providing a basis for the concomitant use of AR antagonists with PI3K/mTOR inhibitors (4). In addition, enhanced therapeutic effects of bicalutamide combined with the PI3K inhibitor GDC-0941 (pictilisib) or the mTOR inhibitor GDC-0980 (apitolisib) have also been also observed in MDA-MB-453 and CAL-148 luminal AR subtype cell xenografts, indicating that the inhibitors targeting the PI3K/mTOR signaling pathway also notably decrease the amount of AR protein (113). It was concluded that AR expression can be regulated post-transcriptionally by activating the RTK, PI3K or Erk1/2 signaling pathways (113). The combination of anti-androgen therapy with targeted therapy against the RTK, PI3K and Erk1/2 signaling pathways may be a promising alternative treatment for AR-positive TNBC.
DNA damage repair pathways
The DNA damage response has recently attracted considerable attention in cancer research. Three major pathways operate in this process: DNA repair mechanisms that remove DNA lesions, cell cycle checkpoints that prevent the growth of cells with DNA damage and apoptotic pathways that eliminate cells with irreparable DNA lesions (114). Among the various types of DNA damage, DNA double-strand breaks (DSB) are of particular interest on account of their function in genomic instability, which promotes tumorigenesis (115). DSB repair is accomplished through the HR or non-homologous end-joining pathways (116). BRCA1 and BRCA2 are critical genes modulating DSB repair through HR (117).
TNBC is commonly associated with BRCA1/2 mutations. A germline mutation in BRCA1 or BRCA2 is present in ~15% of patients with TNBC; TNBC cases account for 70% of cases of breast cancer with BRCA1 mutation, and 16–23% of those with BRCA2 mutation (118). TNBC also has similar clinical and pathological features as breast cancer with a BRCA1/2 mutation. For instance, the patients are more likely to be young and present with a high grade and lymph node invasion ratio (119,120). In addition, BRCA1/2 mutations have been confirmed to be indicators of a poor TNBC prognosis (121). In a study of 182 women with TNBC, >50% were carrying inherited BRCA1 mutations, thus demonstrating the close association between TNBC and BRCA1 (122).
Polyadenosine 5′-diphosphoribose produced by PARP enzymes serves an important role in the repair of DNA damage (123). Where there is a defect in DNA repair genes, such as BRCA in TNBC, a PARP inhibitor may be a desirable choice for therapy. In an open-label phase II clinical study, results indicated that the combination of PARP inhibitor iniparib and conventional chemotherapy drugs, including gemcitabine and carboplatin, could produce significant clinical benefit rates (from 34 to 56%; P=0.01) and a high overall response rate (from 32 to 52%; P=0.02) in patients with TNBC. The median progression-free and overall survival times were also prolonged, with an extension from 3.6 to 5.9 months (progression HR, 0.59; P=0.01) and from 7.7 to 12.3 months (mortality HR, 0.57; P=0.01), respectively (124). In addition, in a phase I trial of the oral PARP inhibitor olaparib for metastatic TNBC, 7 (37%) out of 19 patients receiving olaparib in combination with weekly paclitaxel had confirmed partial responses (125). Data regarding the safety of PARP inhibitor treatment for advanced TNBC and/or BRCA-mutated breast cancer from clinical trials is summarized in Table I; the side effects of PARP inhibitors are well tolerated. Interestingly, in the TNBC patients with BRCA downregulation, the sensitivity to PARP inhibitor treatment was enhanced when combined with PI3K inhibition, as the blockade of PI3K impaired HR, inducing sensitization to PARP inhibitors (44), providing a theoretical basis for the combination of PI3K with PARP inhibitors for these patients.
In addition to the aforementioned BRCA1/2 genes, other breast cancer predisposition genes, including RAD51D, MRE11A, checkpoint kinase 2, mutL homolog 1, mutS homolog 6 and partner and localizer of BRCA2, have been confirmed to be associated with the development and progression of TNBC (126). It was previously reported that the cytoplasmic expression and lack of nuclear expression of RAD51 were associated with TN phenotypes, the aberrant expression of BRCA1 and a poor prognosis for patients (127), indicating that RAD51 may be a promising biomarker for selecting patients who are suitable for treatment with DNA-damaging agents.
Immunoregulatory tumor microenvironment
An increasing number of studies have demonstrated that the tumor microenvironment, particularly the immune microenvironment, is associated with the development and progression of breast cancer (128). Lehmann et al (4) and Burstein et al (10) reported that a subtype of TNBC displayed upregulated immunological responses, immune cell markers and immune transcription factors, implying the dysregulation of immune pathways in TNBC, and that the immunotherapeutic approach may be a valuable treatment strategy for patients with TNBC (4,10).
Tumor infiltrating lymphocytes
High levels of stromal lymphocytic infiltration was confirmed to be associated with improved TNBC prognosis in two adjuvant phase III trials. Results of one trial indicated that compared with the patients who had a lower level of stromal lymphocytic infiltration, patients with high lymphocytic infiltration had a 14% reduced risk of recurrence (P=0.02), an 18% reduced risk of distant recurrence (P=0.04) and a 19% reduced risk of mortality (P=0.01) for every 10% increase in stromal lymphocytic infiltration (129). Another phase III randomized adjuvant breast cancer trial reported similar results, indicating that an increase in lymphocytic infiltration was associated with an improved prognosis in node-positive and ER-negative/HER2-negative breast cancer, regardless of chemotherapy (130). In addition, the presence of tumor-infiltrating lymphocytes predicted a better clinical response to neoadjuvant chemotherapy (131). Therefore, the existence of tumor-infiltrating lymphocytes can be regarded as a prognostic parameter for the prediction of the response to clinical treatment of patients with TNBC.
Immune checkpoint system
Tumor cells can evade the recognition and destruction by the host immune system through the immune checkpoint system; blocking the immune checkpoint system is a promising treatment for achieving effective antitumor immunity. PD-1 is a well-established immune checkpoint protein and cell-surface receptor that disrupts the T-cell response by triggering inhibitory pathways (132). Notably, PD-1 is expressed in 20% of TNBC tumors (133). PD-L1 is the ligand of PD-1, and is expressed in 58.6% of TNBC tumors (66,134). PD-L2 is expressed on the surface of dendritic cells, macrophages, mast cells and B cells (135). Antibodies to inhibit PD-1 signaling are currently being assessed for clinical use. For example, pembrolizumab, a monoclonal antibody against PD-1, has demonstrated an overall response rate of 18.5% in a phase Ib study (n=32) of patients with PD-L1-positive TNBCs (66). Furthermore, a preliminary phase I trial study suggested that the monoclonal anti-PD-L1 antibody MPDL3280A prolonged progression-free survival time and produced durable therapeutic effects in certain patients with TNBC (136).
In addition, there is an association between the immune response and the Ras/MAPK pathway in TNBC. A study has indicated that the Ras/MAPK pathway negatively regulated antitumor immunity by affecting antigen presentation, including that of MHC-I, MHC-II and PD-1, and it was verified that a combination of MEK inhibition and PD-1/PD-L1 antibodies increased the effect of treatment in murine syngeneic tumor models (26). An additional study identified that an oncolytic viral therapy (NV1066) eliminated >70% of the cells from all the TNBC cell lines tested by day 7, and effectively reduced the tumor size compared with control treatment groups (57 vs. 438 mm; P=0.002) through downregulating the Ras/MAPK pathway (137).
Conclusion
TNBC is attracting increasing attention on account of its unique clinical pathology and molecular features. Chemotherapy remains the exclusive effective systemic treatment for patients with TNBC. These patients exhibit varied therapeutic responses and prognoses. Thus, individualized treatment and prognostic analysis in patients with TNBC can be difficult, particularly when this depends on conventional clinical and pathological features, including the histological grade, primary tumor size, lymph node metastasis status and ER/PR/HER2 expression. With the emergence of targeted therapy, screening more reliable molecular markers is imperative, and comprehensively understanding the signaling pathways that regulate biological behaviors may facilitate the establishment of a precise molecular classification for TNBC and effective therapeutic regimens.
In the present review, TNBC-associated tumorigenic signaling pathways were summarized in five categories, specifically RTKs and downstream signaling pathways, epithelial-to-mesenchymal transition and associated pathways, immunoregulatory tumor microenvironment, DNA damage repair pathways, and AR and coordinating pathways. These pathways are illustrated in Fig. 1 to demonstrate the interactions across the entire network, and the relevant drugs against specific pathways are summarized in Table I. Enhancing the understanding of the molecular heterogeneity of TNBCs can lay the foundation for the individualized treatment of patients with TNBC.
It is worth noting that a study concerning the efficacy of a number of biological agents, including bevacizumab, sunitinib, sorafenib, lapatinib, iniparib and cetuximab, in metastatic TNBCs indicated that a significant PFS improvement was obtained following treatment with bevacizumab or cetuximab, indicating the importance of targeted therapy. Regrettably, the impact of the other agents in the study on patient survival was not significant (138), possibly due to concurrent abnormalities occurring in a number of the patients. If that is correct, the concurrent inhibition of tumorigenic pathways may inhibit the cancer process (45). Therefore, the understanding of the signaling crosstalk and feedback among the TNBC-associated tumorigenic signaling pathways needs to be improved to allow effective treatments with tolerable side effects to be developed.
Acknowledgements
Not applicable.
Funding
This work was supported by the Key Projects in the National Science & Technology Pillar Program (grant nos. 2015BAl12B12 and 2015BAl12B15), National Natural Science Foundation of China (grant nos. 81472473 and 81272360) and Tianjin Municipal Commission of Science & Technology Key Research Program (grant no. 13ZCZCSY20300).
Availability of data and materials
Not applicable.
Authors' contributions
NW led the review's designing, consulting and writing. JL and JY led the conception and review of the paper. JZhang, JZhao, KM, JuZ, and ZJ made contributions to the collection of relevant literature. All authors have read and approved the manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
AbbreviationsALDH1
aldehyde dehydrogenase 1
AR
androgen receptor
BRCA
breast cancer-associated
Co-Smads
common mediator Smads
DSB
DNA double-strand break
EGFR
epidermal growth factor receptor
EMT
epithelial-to-mesenchymal transition
ER
estrogen receptor
Erk
extracellular signal-regulated kinase
FGFR
fibroblast growth factor receptor
HER2
human epidermal growth factor receptor 2
I-Smads
inhibitory Smads
IGFR
insulin-like growth factor receptor
LRP5/6
low-density lipoprotein receptor-related 5/6
MAPK
mitogen-activated protein kinase
MEK
mitogen-activated protein kinase kinase 1
mTOR
mechanistic target of rapamycin
PARP
poly(ADP-ribose) polymerase
PD-1
programmed death-1
PD-L1
programmed death-ligand 1
PDGFR
platelet-derived growth factor receptor
PI3K
phosphoinositide 3-kinase
PIP2
phosphatidylinositol-4,5-diphosphate
PIP3
phosphatidylinositol-3,4,5-triphosphate
PR
progesterone receptor
PTEN
phosphatase and tensin homolog
R-Smads
receptor-regulated Smads
RTKs
Receptor tyrosine kinases
SHP2
Src homology phosphotyrosyl phosphatase 2
TGFR-β
transforming growth factor receptor-β
TNBC
triple-negative breast cancer
ReferencesTorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin6587108201510.3322/caac.2126225651787BrentonJDCareyLAAhmedAACaldasCMolecular classification and molecular forecasting of breast cancer: Ready for clinical application?J Clin Oncol2373507360200510.1200/JCO.2005.03.384516145060ShahSPRothAGoyaROloumiAHaGZhaoYTurashviliGDingJTseKHaffariGThe clonal and mutational evolution spectrum of primary triple-negative breast cancersNature486395399201210.1038/nature1093322495314LehmannBDBauerJAChenXSandersMEChakravarthyABShyrYPietenpolJAIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest12127502767201110.1172/JCI4501421633166DentRTrudeauMPritchardKIHannaWMKahnHKSawkaCALickleyLARawlinsonESunPNarodSATriple-negative breast cancer: Clinical features and patterns of recurrenceClin Cancer Res1344294434200710.1158/1078-0432.CCR-06-304517671126GluzOLiedtkeCGottschalkNPusztaiLNitzUHarbeckNTriple-negative breast cancer-current status and future directionsAnn Oncol2019131927200910.1093/annonc/mdp49219901010BerryDACirrincioneCHendersonICCitronMLBudmanDRGoldsteinLJMartinoSPerezEAMussHBNortonLEstrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerJAMA29516581667200610.1001/jama.295.14.165816609087NabholtzJMAbrialCMouret-ReynierMADauplatMMWeberBGligorovJForestAMTredanOVanlemmensLPetitTMulticentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: Identification of biologically defined signatures predicting treatment impactAnn Oncol2515701577201410.1093/annonc/mdu18324827135TorrisiRBalduzziAGhisiniRRoccaABottiglieriLGiovanardiFVeronesiPLuiniAOrlandoLVialeGTailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxelCancer Chemother Pharmacol62667672200810.1007/s00280-007-0652-z18064460BursteinMDTsimelzonAPoageGMCovingtonKRContrerasAFuquaSASavageMIOsborneCKHilsenbeckSGChangJCComprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancerClin Cancer Res2116881698201510.1158/1078-0432.CCR-14-043225208879TsimberidouAMIskanderNGHongDSWhelerJJFalchookGSFuSPiha-PaulSNaingAJankuFLuthraRPersonalized medicine in a phase I clinical trials program: The MD Anderson cancer center initiativeClin Cancer Res1863736383201210.1158/1078-0432.CCR-12-162722966018JovanovićBBeelerJSPickupMWChytilAGorskaAEAshbyWJLehmannBDZijlstraAPietenpolJAMosesHLTransforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancerBreast Cancer Res16R69201410.1186/bcr368424985072LitzenburgerBCCreightonCJTsimelzonAChanBTHilsenbeckSGWangTCarboniJMGottardisMMHuangFChangJCHigh IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapyClin Cancer Res1723142327201110.1158/1078-0432.CCR-10-190321177763SharpeRPearsonAHerrera-AbreuMTJohnsonDMackayAWeltiJCNatrajanRReynoldsARReis-FilhoJSAshworthATurnerNCFGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivoClin Cancer Res1752755286201110.1158/1078-0432.CCR-10-272721712446SpanheimerPMLorenzenAWDe AndradeJPKulakMVCarrJCWoodfieldGWSuggSLWeigelRJReceptor tyrosine kinase expression predicts response to sunitinib in breast cancerAnn Surg Oncol2242874294201510.1245/s10434-015-4597-x25971960YanSJiaoXZouHLiKPrognostic significance of c-Met in breast cancer: A meta-analysis of 6010 casesDiagn Pathol1062201510.1186/s13000-015-0296-y26047809BurnessMLGrushkoTAOlopadeOIEpidermal growth factor receptor in triple-negative and basal-like breast cancer: Promising clinical target or only a marker?Cancer J162332201010.1097/PPO.0b013e3181d24fc120164687SiziopikouKPArigaRProussaloglouKEGattusoPCobleighMThe challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: A promising candidate for epidermal growth factor receptor-targeted therapy?Breast J12360362200610.1111/j.1075-122X.2006.00276.x16848847BayraktarSGlückSMolecularly targeted therapies for metastatic triple-negative breast cancerBreast Cancer Res Treat1382135201310.1007/s10549-013-2421-523358903HsiaoYCYehMHChenYJLiuJFTangCHHuangWCLapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6Oncotarget63796537978201510.18632/oncotarget.570026513016AgazieYMHaymanMJMolecular mechanism for a role of SHP2 in epidermal growth factor receptor signalingMol Cell Biol2378757886200310.1128/MCB.23.21.7875-7886.200314560030MatalkahFMartinEZhaoHAgazieYMSHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancerBreast Cancer Res182201610.1186/s13058-015-0659-z26728598KimHRJungKHImSAImYHKangSYParkKHLeeSKimSBLeeKHAhnJSMulticentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)Ann Oncol2414851490201310.1093/annonc/mds65823380385GerberBLoiblSEidtmannHRezaiMFaschingPATeschHEggemannHSchraderIKittelKHanuschCNeoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)Ann Oncol2429782984201310.1093/annonc/mdt36124136883BartholomeuszCXieXPitnerMKKondoKDadbinALeeJSasoHSmithPDDalbyKNUenoNTMEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft modelMol Cancer Ther1427732781201510.1158/1535-7163.MCT-15-024326384399GiltnaneJMBalkoJMRationale for targeting the Ras/MAPK pathway in triple-negative breast cancerDiscov Med17275283201424882719BartholomeuszCGonzalez-AnguloAMLiuPHayashiNLluchAFerrer-LozanoJHortobágyiGNHigh ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patientsOncologist17766774201210.1634/theoncologist.2011-037722584435LoiSDushyanthenSBeavisPASalgadoRDenkertCSavasPCombsSRimmDLGiltnaneJMEstradaMVRAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: Therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitorsClin Cancer Res2214991509201610.1158/1078-0432.CCR-15-112526515496RamehLECantleyLCThe role of phosphoinositide 3-kinase lipid products in cell functionJ Biol Chem27483478350199910.1074/jbc.274.13.834710085060BaselgaJTargeting the phosphoinositide-3 (PI3) kinase pathway in breast cancerOncologist16Suppl 1S12S19201110.1634/theoncologist.2011-S1-12CantleyLCThe phosphoinositide 3-kinase pathwayScience29616551657200210.1126/science.296.5573.165512040186SalmenaLCarracedoAPandolfiPPTenets of PTEN tumor suppressionCell133403414200810.1016/j.cell.2008.04.01318455982Meric-BernstamFGonzalez-AnguloAMTargeting the mTOR signaling network for cancer therapyJ Clin Oncol2722782287200910.1200/JCO.2008.20.076619332717Cossu-RoccaPOrrùSMuroniMRSangesFSotgiuGEnaSPiraGMurgiaLMancaAUrasMGAnalysis of PIK3CA mutations and activation pathways in triple negative breast cancerPLoS One10e0141763201510.1371/journal.pone.014176326540293Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature4906170201210.1038/nature1141223000897KorkayaHPaulsonACharafe-JauffretEGinestierCBrownMDutcherJClouthierSGWichaMSRegulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signalingPLoS Biol7e1000121200910.1371/journal.pbio.100012119492080ShrivastavaSKulkarniPThummuriDJeengarMKNaiduVGAlvalaMRedddyGBRamakrishnaSPiperlongumine, an alkaloid causes inhibition of PI3K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cellsApoptosis1911481164201410.1007/s10495-014-0991-224729100ChinYRYoshidaTMarusykABeckAHPolyakKTokerATargeting Akt3 signaling in triple-negative breast cancerCancer Res74964973201410.1158/0008-5472.CAN-13-217524335962MonteroJCEsparis-OgandoARe-LouhauMFSeoaneSAbadMCaleroROcañaAPandiellaAActive kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancerOncogene33148156201410.1038/onc.2012.57223246963BaselgaJCamponeMPiccartMBurrisHAIIIRugoHSSahmoudTNoguchiSGnantMPritchardKILebrunFEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med366520529201210.1056/NEJMoa110965322149876BeuvinkIBoulayAFumagalliSZilbermannFRuetzSO'ReillyTNattFHallJLaneHAThomasGThe mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translationCell120747759200510.1016/j.cell.2004.12.04015797377SinghJNovikYSteinSVolmMMeyersMSmithJOmeneCSpeyerJSchneiderRJhaveriKPhase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancerBreast Cancer Res16R32201410.1186/bcr363424684785GanesanPMoulderSLeeJJJankuFValeroVZinnerRGNaingAFuSTsimberidouAMHongDTriple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: Improved outcomes with combination chemotherapy and targeted agentsMol Cancer Ther1331753184201410.1158/1535-7163.MCT-14-035825253784IbrahimYHGarcia-GarciaCSerraVHeLTorres-LockhartKPratAAntonPCozarPGuzmánMGruesoJPI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibitionCancer Discov210361047201210.1158/2159-8290.CD-11-034822915752SchulerMAwadaAHarterPCanonJLPossingerKSchmidtMDe GrèveJNevenPDirixLJonatWA phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerBreast Cancer Res Treat13411491159201210.1007/s10549-012-2126-122763464BernsdorfMIngvarCJörgensenLTuxenMKJakobsenEHSaetersdalAKimper-KarlMLKromanNBalslevEEjlertsenBEffect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trialBreast Cancer Res Treat126463470201110.1007/s10549-011-1352-221234672MailliezABaldiniCVanJTServentVMalletYBonneterreJNasal septum perforation: A side effect of bevacizumab chemotherapy in breast cancer patientsBr J Cancer103772775201010.1038/sj.bjc.660582820736943ScottAJMessersmithWAJimenoAApatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumorsDrugs Today (Barc)51223229201510.1358/dot.2015.51.4.232059926020064HongDSGarrido-LagunaIEkmekciogluSFalchookGSNaingAWhelerJJFuSMoulderSLPiha-PaulSTsimberidouAMDual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumorsCancer12021642173201410.1002/cncr.2870124752867TolaneySMTanSGuoHBarryWVan AllenEWagleNBrockJLarrabeeKPaweletzCIvanovaEPhase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerInvest New Drugs3311081114201510.1007/s10637-015-0269-826123926TolaneySMZiehrDRGuoHNgMRBarryWTHigginsMJIsakoffSJBrockJEIvanovaEVPaweletzCPPhase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patientsOncologist222532201710.1634/theoncologist.2016-022927789775SoriaJCDeBraudFBahledaRAdamoBAndreFDienstmannRDelmonteACeredaRIsaacsonJLittenJPhase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsAnn Oncol2522442251201410.1093/annonc/mdu39025193991WuYLZhangLITrandafirLDongTDuvalVHazellKXuBPhase I study of the Pan-PI3K inhibitor buparlisib in adult chinese patients with advanced solid tumorsAnticancer Res3661856194201610.21873/anticanres.1121227793950JuricDKropIRamanathanRKWilsonTRWareJASanabria BohorquezSMSavageHMSampathDSalphatiLLinRSPhase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumorsCancer Discov7704715201710.1158/2159-8290.CD-16-108028331003TamuraKHashimotoJTanabeYKodairaMYonemoriKSetoTHiraiFAritaSToyokawaGChenLSafety and tolerability of AZD5363 in Japanese patients with advanced solid tumorsCancer Chemother Pharmacol77787795201610.1007/s00280-016-2987-926931343DoiTTamuraKTanabeYYonemoriKYoshinoTFuseNKodairaMBandoHNoguchiKShimamotoTOhtsuAPhase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumorsCancer Chemother Pharmacol76409416201510.1007/s00280-015-2810-z26104654SauraCRodaDRosellóSOliveiraMMacarullaTPérez-FidalgoJAMorales-BarreraRSanchis-GarcíaJMMusibLBudhaNA first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumorsCancer Discov7102113201710.1158/2159-8290.CD-16-051227872130PascualTApellániz-RuizMPernautCCueto-FelguerosoCVillalbaPÁlvarezCMansoLInglada-PérezLRobledoMRodríguez-AntonaCCiruelosEPolymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancerPLoS One12e0180192201710.1371/journal.pone.018019228727815ChiuJWHotteSJKollmannsbergerCKRenoufDJCesconDWHedleyDChowSMoscowJChenZPerryMA phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI 9041)Invest New Drugs34104111201610.1007/s10637-015-0313-826686201SchwartzbergLSYardleyDAEliasADPatelMLoRussoPBurrisHAGucalpAPetersonACBlaneyMESteinbergJLA Phase I/Ib study of enzalutamide alone and in combination with endocrine therapies in women with advanced breast cancerClin Cancer Res2340464054201710.1158/1078-0432.CCR-16-233928280092DrewYLedermannJHallGReaDGlasspoolRHighleyMJaysonGSluddenJMurrayJJamiesonDPhase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerBr J Cancer114e21201610.1038/bjc.2016.13327228289O'ShaughnessyJSchwartzbergLDansoMAMillerKDRugoHSNeubauerMRobertNHellerstedtBSalehMRichardsPPhase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancerJ Clin Oncol3238403847201410.1200/JCO.2014.55.298425349301NishikawaTMatsumotoKTamuraKYoshidaHImaiYMiyasakaAOnoeTYamaguchiSShimizuCYonemoriKPhase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumorsCancer Sci10818341842201710.1111/cas.1330728665051de BonoJRamanathanRKMinaLChughRGlaspyJRafiiSKayeSSachdevJHeymachJSmithDCPhase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancersCancer Discov7620629201710.1158/2159-8290.CD-16-125028242752RobsonMImSASenkusEXuBDomchekSMMasudaNDelalogeSLiWTungNArmstrongAOlaparib for metastatic breast cancer in patients with a germline BRCA mutationN Engl J Med377523533201710.1056/NEJMoa170645028578601NandaRChowLQDeesECBergerRGuptaSGevaRPusztaiLPathirajaKAktanGChengJDPembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 studyJ Clin Oncol3424602467201610.1200/JCO.2015.64.893127138582LeeJMCimino-MathewsAPeerCJZimmerALipkowitzSAnnunziataCMCaoLHarrellMISwisherEMHoustonNSafety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-Ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1–3 inhibitor cediranib in women's cancers: A dose-escalation, phase I studyJ Clin Oncol3521932202201710.1200/JCO.2016.72.134028471727HoeflichKPO'BrienCBoydZCavetGGuerreroSJungKJanuarioTSavageHPunnooseETruongTIn vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer modelsClin Cancer Res1546494664200910.1158/1078-0432.CCR-09-031719567590BrittenCDPI3K and MEK inhibitor combinations: Examining the evidence in selected tumor typesCancer Chemother Pharmacol7113951409201310.1007/s00280-013-2121-123443307NietoMAEpithelial plasticity: A common theme in embryonic and cancer cellsScience3421234850201310.1126/science.123485024202173Al MoustafaAEAchkharAYasmeenAEGF-receptor signaling and epithelial-mesenchymal transition in human carcinomasFront Biosci (Schol Ed)4671684201210.2741/s29222202084GonzalezDMMediciDSignaling mechanisms of the epithelial-mesenchymal transitionSci Signal7re8201410.1126/scisignal.200518925249658GuarinoMSrc signaling in cancer invasionJ Cell Physiol2231426201020049846HungCMKuoDHChouCHSuYCHoCTWayTDOsthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cellsJ Agric Food Chem5996839690201110.1021/jf202148921806057KangYMassaguéJEpithelial-mesenchymal transitions: Twist in development and metastasisCell118277279200410.1016/j.cell.2004.07.01115294153SivakumarRKogaHSelvendiranKMaeyamaMUenoTSataMAutocrine loop for IGF-I receptor signaling in SLUG-mediated epithelial-mesenchymal transitionInt J Oncol34329338200919148466Vincent-SalomonAThieryJPHost microenvironment in breast cancer development: Epithelial-mesenchymal transition in breast cancer developmentBreast Cancer Res5101106200310.1186/bcr57812631389De CraeneBBerxGRegulatory networks defining EMT during cancer initiation and progressionNat Rev Cancer1397110201310.1038/nrc344723344542ThieryJPEpithelial-mesenchymal transitions in tumour progressionNat Rev Cancer2442454200210.1038/nrc82212189386ForoniCBrogginiMGeneraliDDamiaGEpithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impactCancer Treat Rev38689697201210.1016/j.ctrv.2011.11.00122118888PratAParkerJSKarginovaOFanCLivasyCHerschkowitzJIHeXPerouCMPhenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Res12R68201010.1186/bcr263520813035ManiSAGuoWLiaoMJEatonENAyyananAZhouAYBrooksMReinhardFZhangCCShipitsinMThe epithelial-mesenchymal transition generates cells with properties of stem cellsCell133704715200810.1016/j.cell.2008.03.02718485877SinghRMoYYRole of microRNAs in breast cancerCancer Biol Ther14201212201310.4161/cbt.2329623291983RhodesLVMartinECSegarHCMillerDFBuechleinARuschDBNephewKPBurowMECollins-BurowBMDual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancerOncotarget61663816652201510.18632/oncotarget.318426062653ItoKParkSHNayakAByerlyJHIrieHYPTK6 inhibition suppresses metastases of triple-negative breast cancer via SNAIL-Dependent E-cadherin regulationCancer Res7644064417201610.1158/0008-5472.CAN-15-344527302163Al-HajjMWichaMSBenito-HernandezAMorrisonSJClarkeMFProspective identification of tumorigenic breast cancer cellsProc Natl Acad Sci USA10039833988200310.1073/pnas.053029110012629218GinestierCHurMHCharafe-JauffretEMonvilleFDutcherJBrownMJacquemierJViensPKleerCGLiuSALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcomeCell Stem Cell1555567200710.1016/j.stem.2007.08.01418371393RhodesLVTateCRSegarHCBurksHEPhamduyTBHoangVElliottSGilliamDPounderFNAnbalaganMSuppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulatorsBreast Cancer Res Treat145593604201410.1007/s10549-014-2979-624810497KahnMCan we safely target the WNT pathway?Nat Rev Drug Discov13513532201410.1038/nrd423324981364Conacci-SorrellMSimchaIBen-YedidiaTBlechmanJSavagnerPBen-Ze'evAAutoregulation of E-cadherin expression by cadherin-cadherin interactions: The roles of beta-catenin signaling, Slug, and MAPKJ Cell Biol163847857200310.1083/jcb.20030816214623871HoweLRWatanabeOLeonardJBrownAMTwist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiationCancer Res6319061913200312702582MacDonaldBTTamaiKHeXWnt/beta-catenin signaling: Components, mechanisms, and diseasesDev Cell17926200910.1016/j.devcel.2009.06.01619619488DeyNBarwickBGMorenoCSOrdanic-KodaniMChenZOprea-IliesGTangWCatzavelosCKerstannKFSledgeGWJrWnt signaling in triple negative breast cancer is associated with metastasisBMC Cancer13537201310.1186/1471-2407-13-53724209998LiYLiPKRobertsMJArendRCSamantRSBuchsbaumDJMulti-targeted therapy of cancer by niclosamide: A new application for an old drugCancer Lett349814201410.1016/j.canlet.2014.04.00324732808Londoño-JoshiAIArendRCAristizabalLLuWSamantRSMetgeBJHidalgoBGrizzleWEConnerMForero-TorresAEffect of niclosamide on basal-like breast cancersMol Cancer Ther13800811201410.1158/1535-7163.MCT-13-055524552774KovalAAhmedKKatanaevVLInhibition of Wnt signalling and breast tumour growth by the multi-purpose drug suramin through suppression of heterotrimeric G proteins and Wnt endocytosisBiochem J473371381201610.1042/BJ2015091326604320NamJSSucharAMKangMJStueltenCHTangBMichalowskaAMFisherLWFedarkoNSJainAPinkasJBone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancerCancer Res6663276335200610.1158/0008-5472.CAN-06-006816778210ZuXZhangQCaoRLiuJZhongJWenGCaoDTransforming growth factor-β signaling in tumor initiation, progression and therapy in breast cancer: An updateCell Tissue Res3477384201210.1007/s00441-011-1225-321845401ShiYMassaguéJMechanisms of TGF-beta signaling from cell membrane to the nucleusCell113685700200310.1016/S0092-8674(03)00432-X12809600KatzLHLiYChenJSMuñozNMMajumdarAChenJMishraLTargeting TGF-β signaling in cancerExpert Opin Ther Targets17743760201310.1517/14728222.2013.78228723651053ValcourtUKowanetzMNiimiHHeldinCHMoustakasATGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transitionMol Biol Cell1619872002200510.1091/mbc.e04-08-065815689496MassaguéJTGFbeta in cancerCell134215230200810.1016/j.cell.2008.07.00118662538KimSLeeJJeonMLeeJENamSJZerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathwayOncotarget715441558201626637807Wahdan-AlaswadRHarrellJCFanZEdgertonSMLiuBThorADMetformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancerCell Cycle1510461059201610.1080/15384101.2016.115243226919310BholaNEBalkoJMDuggerTCKubaMGSánchezVSandersMStanfordJCookRSArteagaCLTGF-β inhibition enhances chemotherapy action against triple-negative breast cancerJ Clin Invest12313481358201310.1172/JCI6541623391723PurringtonKSVisscherDWWangCYannoukakosDHamannUNevanlinnaHCoxAGilesGGEckel-PassowJELakisSGenes associated with histopathologic features of triple negative breast tumors predict molecular subtypesBreast Cancer Res Treat157117131201610.1007/s10549-016-3775-227083182CollinsLCColeKSMarottiJDHuRSchnittSJTamimiRMAndrogen receptor expression in breast cancer in relation to molecular phenotype: Results from the nurses' health studyMod Pathol24924931201110.1038/modpathol.2011.5421552212LiaoDJDicksonRBRoles of androgens in the development, growth, and carcinogenesis of the mammary glandJ Steroid Biochem Mol Biol80175189200210.1016/S0960-0760(01)00185-611897502HickeyTERobinsonJLCarrollJSTilleyWDMinireview: the androgen receptor in breast tissues: Growth inhibitor, tumor suppressor, oncogene?Mol Endocrinol2612521267201210.1210/me.2012-110722745190GucalpATrainaTATriple-negative breast cancer: Role of the androgen receptorCancer J166265201010.1097/PPO.0b013e3181ce4ae120164692GucalpATolaneySIsakoffSJIngleJNLiuMCCareyLABlackwellKRugoHNabellLForeroAPhase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancerClin Cancer Res1955055512201310.1158/1078-0432.CCR-12-332723965901LehmannBDBauerJASchaferJMPendletonCSTangLJohnsonKCChenXBalkoJMGómezHArteagaCLPIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitorsBreast Cancer Res16406201410.1186/s13058-014-0406-x25103565Cuenca-LópezMdMonteroJCMoralesJCPratAPandiellaAOcanaAPhospho-kinase profile of triple negative breast cancer and androgen receptor signalingBMC Cancer14302201410.1186/1471-2407-14-30224779793Maugeri-SaccàMBartucciMDe MariaRDNA damage repair pathways in cancer stem cellsMol Cancer Ther1116271636201210.1158/1535-7163.MCT-11-104022844074PierceAJStarkJMAraujoFDMoynahanMEBerwickMJasinMDouble-strand breaks and tumorigenesisTrends Cell Biol11S52S59200110.1016/S0962-8924(01)82296-011684443PowellSNKachnicLARoles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiationOncogene2257845791200310.1038/sj.onc.120667812947386BouwmanPJonkersJThe effects of deregulated DNA damage signalling on cancer chemotherapy response and resistanceNat Rev Cancer12587598201210.1038/nrc334222918414StevensKNVachonCMCouchFJGenetic susceptibility to triple-negative breast cancerCancer Res7320252030201310.1158/0008-5472.CAN-12-169923536562AtchleyDPAlbarracinCTLopezAValeroVAmosCIGonzalez-AnguloAMHortobagyiGNArunBKClinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast canceJ Clin Oncol2642824288200810.1200/JCO.2008.16.623118779615GoodwinPJPhillipsKAWestDWEnnisMHopperJLJohnEMO'MalleyFPMilneRLAndrulisILFriedlanderMLBreast cancer prognosis in BRCA1 and BRCA2 mutation carriers: An international prospective breast cancer family registry population-based cohort studyJ Clin Oncol301926201210.1200/JCO.2010.33.006822147742Stoppa-LyonnetDAnsquerYDreyfusHGautierCGauthier-VillarsMBourstynECloughKBMagdelénatHPouillartPVincent-SalomonAFamilial invasive breast cancers: Worse outcome related to BRCA1 mutationsJ Clin Oncol1840534059200010.1200/JCO.2000.18.24.405311118466RummelSVarnerEShriverCDEllsworthREEvaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancerBreast Cancer Res Treat137119125201310.1007/s10549-012-2348-223192404HoeijmakersJHGenome maintenance mechanisms for preventing cancerNature411366374200110.1038/3507723211357144O'ShaughnessyJOsborneCPippenJEYoffeMPattDRochaCKooICShermanBMBradleyCIniparib plus chemotherapy in metastatic triple-negative breast cancerN Engl J Med364205214201110.1056/NEJMoa101141821208101DentRALindemanGJClemonsMWildiersHChanAMcCarthyNJSingerCFLoweESWatkinsCLCarmichaelJPhase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerBreast Cancer Res15R88201310.1186/bcr348424063698OllierMRadosevic-RobinNKwiatkowskiFPonelleFVialaSPrivatMUhrhammerNBernard-GallonDPenault-LlorcaFBignonYJBidetYDNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predispositionAm J Cancer Res521132126201526328243AlshareedaATNegmOHAleskandaranyMAGreenARNolanCTigHhePJMadhusudanSEllisIORakhaEAClinical and biological significance of RAD51 expression in breast cancer: A key DNA damage response proteinBreast Cancer Res Treat1594153201610.1007/s10549-016-3915-827464795LoiSMichielsSSalgadoRSirtaineNJoseVFumagalliDKellokumpu-LehtinenPLBonoPKatajaVDesmedtCTumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trialAnn Oncol2515441550201410.1093/annonc/mdu11224608200AdamsSGrayRJDemariaSGoldsteinLPerezEAShulmanLNMartinoSWangMJonesVESaphnerTJPrognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199J Clin Oncol3229592966201410.1200/JCO.2013.55.049125071121LoiSSirtaineNPietteFSalgadoRVialeGVan EenooFRouasGFrancisPCrownJPHitreEPrognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98J Clin Oncol31860867201310.1200/JCO.2011.41.090223341518AdamsSGoldsteinLJSparanoJADemariaSBadveSSTumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC)Oncoimmunology4e985930201510.4161/2162402X.2014.98593026405612CriscitielloCCuriglianoGImmunotherapy of breast cancerProg Tumor Res423043201510.1159/00043718326377084MittendorfEAPhilipsAVMeric-BernstamFQiaoNWuYHarringtonSSuXWangYGonzalez-AnguloAMAkcakanatAPD-L1 expression in triple-negative breast cancerCancer Immunol Res2361370201410.1158/2326-6066.CIR-13-012724764583DongHStromeSESalomaoDRTamuraHHiranoFFliesDBRochePCLuJZhuGTamadaKTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNat Med8793800200210.1038/nm0902-1039c12091876TopalianSLHodiFSBrahmerJRGettingerSNSmithDCMcDermottDFPowderlyJDCarvajalRDSosmanJAAtkinsMBSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med36624432454201210.1056/NEJMoa120069022658127Immunotherapy slows TNBC progressionCancer Discov5570201510.1158/2159-8290.CD-NB2015-059GholamiSChenCHGaoSLouEFujisawaSCarsonJNnoliJEChouTCBrombergJFongYRole of MAPK in oncolytic herpes viral therapy in triple-negative breast cancerCancer Gene Ther21283289201410.1038/cgt.2014.2824924199BramatiAGirelliSTorriVFarinaGGalfrascoliEPivaSMorettiADazzaniMCSburlatiPLa VerdeNMEfficacy of biological agents in metastatic triple-negative breast cancerCancer Treat Rev40605613201410.1016/j.ctrv.2014.01.00324529896
Molecular mechanisms of TNBC. RTKs promote tumorigenesis through the Ras/mitogen-activated protein kinase and PI3K/Akt/mTOR pathways. The phosphorylation of ERK, the Wnt/β-catenin pathway and the TGF-β/Smad pathway activates EMT, and regulates the migration and invasion of tumor cells. In the AR pathway, AR can bind to chaperone proteins to promote the transcription of target genes in the nucleus. At the genetic level, BRCA1/2 mutations can also promote the development of TNBCs. In the tumor microenvironment, tumor-infiltrating lymphocytes and the immune checkpoint system can allow evasion from recognition by the host immune system. TNBC, triple negative breast cancer; RTK, receptor tyrosine kinase; PI3K, phosphoinositide 3-kinase; mTOR, mechanistic target of rapamycin; ERK, extracellular signal-regulated kinase; TGF, transforming growth factor, EMT, epithelial-mesenchymal transition; AR, androgen receptor; BRCA, breast cancer-associated; PD-(L)1, programmed death (ligand) 1; EGFR, epidermal growth factor receptor; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; IGFR, insulin-like growth factor receptor; LRP, LDL receptor-related protein; Frz, Frizzled; TβR, transforming growth factor β receptor; miRNA, microRNA; GSK3β, glycogen synthase kinase 3β; HSP, heat shock protein; MEK, mitogen-activated protein kinase kinase 1; PIP2, phosphatidylinositol 4,5-bisphosphate; PTEN, phosphatase and tensin homolog; Dvl, Dishevelled; CDKs, cyclin-dependent kinase; HR, homologous recombination; PARP, poly(ADP-ribose) polymerase.
Current clinical trials regarding potential targets in triple-negative breast cancer.